Diversified Consumer Services
Company Overview of Universite De Montreal, L'
2900 BOUL EDOUARD-MONTPETIT
Montreal, QC H3T 1J4
Key Executives for Universite De Montreal, L'
Vice-Rector of Development and Alumni Relations
Compensation as of Fiscal Year 2015.
Universite De Montreal, L' Key Developments
Universite De Montreal, L' Presents at Milken Institute, Global Conference 2015, Apr-27-2015 03:45 PM
Apr 23 15
Universite De Montreal, L' Presents at Milken Institute, Global Conference 2015, Apr-27-2015 03:45 PM. Venue: 2025 Ave Of The Stars, Los Angeles, CA 90067, California, United States. Speakers: Yves Joanette, Professor of Cognitive Neurosciences and Aging.
Universite De Montreal, L' Presents at Canadian Hydropower Association Forum 2014, May-27-2014
May 27 14
Universite De Montreal, L' Presents at Canadian Hydropower Association Forum 2014, May-27-2014 . Venue: Fairmont Château Laurier, 1 Rideau Street, Ottawa, Ontario, Canada. Speakers: Daniel Boisclair.
Domain Therapeutics, Universite de Montreal, IRICoR and McHill University Ink New Licensing Pact on G-Protein Coupled Receptor Biosensor Technology
Dec 23 13
Domain Therapeutics announced the signing of a licensing and partnership agreement on GPCR biosensor technology with Universite de Montreal (UdeM) and its commercialization unit, with the Institute for Research in Immunology and Cancer - Commercialization of Research (IRICoR), as well as with McGill University. The GPCR biosensor technology was developed with the support of a grant from the Quebec Consortium for Drug Discovery (CQDM), whose mission is to fund breakthrough technologies with the financial support of major pharma companies. This project was overseen by a team of researchers from UdeM's Institute for Research in Immunology and Cancer (IRIC) led by Dr. Michel Bouvier. Dr. Bouvier is internationally renowned for his work on GPCRs. The agreement gives Domain Therapeutics co-exclusive access, with AstraZeneca, Merck and Pfizer having access via their participation in the CQDM, to biosensor technology developed by Dr. Bouvier's team. This new approach, which makes it possible to discriminate the functional activation of intracellular signalling pathways associated with GPCRs, is considered a prime technology for accelerating the discovery and development of biased ligands for this class of receptors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|